These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
272 related articles for article (PubMed ID: 20460382)
1. Multifunctional nanoparticles delivering small interfering RNA and doxorubicin overcome drug resistance in cancer. Chen Y; Bathula SR; Li J; Huang L J Biol Chem; 2010 Jul; 285(29):22639-50. PubMed ID: 20460382 [TBL] [Abstract][Full Text] [Related]
2. Nanoparticles targeted with NGR motif deliver c-myc siRNA and doxorubicin for anticancer therapy. Chen Y; Wu JJ; Huang L Mol Ther; 2010 Apr; 18(4):828-34. PubMed ID: 20068551 [TBL] [Abstract][Full Text] [Related]
3. A self-assembled polyjuglanin nanoparticle loaded with doxorubicin and anti-Kras siRNA for attenuating multidrug resistance in human lung cancer. Wen ZM; Jie J; Zhang Y; Liu H; Peng LP Biochem Biophys Res Commun; 2017 Dec; 493(4):1430-1437. PubMed ID: 28958938 [TBL] [Abstract][Full Text] [Related]
4. Sequential treatment of drug-resistant tumors with RGD-modified liposomes containing siRNA or doxorubicin. Jiang J; Yang SJ; Wang JC; Yang LJ; Xu ZZ; Yang T; Liu XY; Zhang Q Eur J Pharm Biopharm; 2010 Oct; 76(2):170-8. PubMed ID: 20600887 [TBL] [Abstract][Full Text] [Related]
5. Delivery of miR-375 and doxorubicin hydrochloride by lipid-coated hollow mesoporous silica nanoparticles to overcome multiple drug resistance in hepatocellular carcinoma. Xue H; Yu Z; Liu Y; Yuan W; Yang T; You J; He X; Lee RJ; Li L; Xu C Int J Nanomedicine; 2017; 12():5271-5287. PubMed ID: 28769563 [TBL] [Abstract][Full Text] [Related]
6. Codelivery of an optimal drug/siRNA combination using mesoporous silica nanoparticles to overcome drug resistance in breast cancer in vitro and in vivo. Meng H; Mai WX; Zhang H; Xue M; Xia T; Lin S; Wang X; Zhao Y; Ji Z; Zink JI; Nel AE ACS Nano; 2013 Feb; 7(2):994-1005. PubMed ID: 23289892 [TBL] [Abstract][Full Text] [Related]
7. Novel polymer micelle mediated co-delivery of doxorubicin and P-glycoprotein siRNA for reversal of multidrug resistance and synergistic tumor therapy. Zhang CG; Zhu WJ; Liu Y; Yuan ZQ; Yang SD; Chen WL; Li JZ; Zhou XF; Liu C; Zhang XN Sci Rep; 2016 Mar; 6():23859. PubMed ID: 27030638 [TBL] [Abstract][Full Text] [Related]
8. Lipid-functionalized dextran nanosystems to overcome multidrug resistance in cancer: a pilot study. Kobayashi E; Iyer AK; Hornicek FJ; Amiji MM; Duan Z Clin Orthop Relat Res; 2013 Mar; 471(3):915-25. PubMed ID: 23011844 [TBL] [Abstract][Full Text] [Related]
9. Inhibition of ABCB1 (MDR1) expression by an siRNA nanoparticulate delivery system to overcome drug resistance in osteosarcoma. Susa M; Iyer AK; Ryu K; Choy E; Hornicek FJ; Mankin H; Milane L; Amiji MM; Duan Z PLoS One; 2010 May; 5(5):e10764. PubMed ID: 20520719 [TBL] [Abstract][Full Text] [Related]
10. Sequential therapy with redox-responsive glucolipid nanocarrier separately delivering siRNA and doxorubicin to overcome multidrug resistance. Meng T; Lu B; Shao S; Yuan M; Liu X; Yuan H; Huang X; Hu F Int J Pharm; 2017 Dec; 534(1-2):368-377. PubMed ID: 29051118 [TBL] [Abstract][Full Text] [Related]
11. Reversal of P-glycoprotein-mediated multidrug resistance by CD44 antibody-targeted nanocomplexes for short hairpin RNA-encoding plasmid DNA delivery. Gu J; Fang X; Hao J; Sha X Biomaterials; 2015 Mar; 45():99-114. PubMed ID: 25662500 [TBL] [Abstract][Full Text] [Related]
12. Enhanced chemotherapy of cancer using pH-sensitive mesoporous silica nanoparticles to antagonize P-glycoprotein-mediated drug resistance. Huang IP; Sun SP; Cheng SH; Lee CH; Wu CY; Yang CS; Lo LW; Lai YK Mol Cancer Ther; 2011 May; 10(5):761-9. PubMed ID: 21411714 [TBL] [Abstract][Full Text] [Related]
13. Surfactin-based nanoparticles loaded with doxorubicin to overcome multidrug resistance in cancers. Huang W; Lang Y; Hakeem A; Lei Y; Gan L; Yang X Int J Nanomedicine; 2018; 13():1723-1736. PubMed ID: 29606866 [TBL] [Abstract][Full Text] [Related]
14. Engineered design of mesoporous silica nanoparticles to deliver doxorubicin and P-glycoprotein siRNA to overcome drug resistance in a cancer cell line. Meng H; Liong M; Xia T; Li Z; Ji Z; Zink JI; Nel AE ACS Nano; 2010 Aug; 4(8):4539-50. PubMed ID: 20731437 [TBL] [Abstract][Full Text] [Related]
15. Pulmonary Codelivery of Doxorubicin and siRNA by pH-Sensitive Nanoparticles for Therapy of Metastatic Lung Cancer. Xu C; Wang P; Zhang J; Tian H; Park K; Chen X Small; 2015 Sep; 11(34):4321-33. PubMed ID: 26136261 [TBL] [Abstract][Full Text] [Related]
16. Multifunctional PLGA Nanobubbles as Theranostic Agents: Combining Doxorubicin and P-gp siRNA Co-Delivery Into Human Breast Cancer Cells and Ultrasound Cellular Imaging. Yang H; Deng L; Li T; Shen X; Yan J; Zuo L; Wu C; Liu Y J Biomed Nanotechnol; 2015 Dec; 11(12):2124-36. PubMed ID: 26510307 [TBL] [Abstract][Full Text] [Related]
17. Novel cationic lipid that delivers siRNA and enhances therapeutic effect in lung cancer cells. Chen Y; Sen J; Bathula SR; Yang Q; Fittipaldi R; Huang L Mol Pharm; 2009; 6(3):696-705. PubMed ID: 19267451 [TBL] [Abstract][Full Text] [Related]
18. Codelivery of doxorubicin and MDR1-siRNA by mesoporous silica nanoparticles-polymerpolyethylenimine to improve oral squamous carcinoma treatment. Wang D; Xu X; Zhang K; Sun B; Wang L; Meng L; Liu Q; Zheng C; Yang B; Sun H Int J Nanomedicine; 2018; 13():187-198. PubMed ID: 29343957 [TBL] [Abstract][Full Text] [Related]
19. The use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistance. Patil YB; Swaminathan SK; Sadhukha T; Ma L; Panyam J Biomaterials; 2010 Jan; 31(2):358-65. PubMed ID: 19800114 [TBL] [Abstract][Full Text] [Related]
20. Reversing of multidrug resistance breast cancer by co-delivery of P-gp siRNA and doxorubicin via folic acid-modified core-shell nanomicelles. Wu Y; Zhang Y; Zhang W; Sun C; Wu J; Tang J Colloids Surf B Biointerfaces; 2016 Feb; 138():60-9. PubMed ID: 26655793 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]